Notice: This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. DERM, XBIT, PROC, PLRX, IMUX, HURA, GALT, VTYX, BHST, and ANIXShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Journey Medical (DERM), XBiotech (XBIT), Procaps Group (PROC), Pliant Therapeutics (PLRX), Immunic (IMUX), TuHURA Biosciences (HURA), Galectin Therapeutics (GALT), Ventyx Biosciences (VTYX), BioHarvest Sciences (BHST), and Anixa Biosciences (ANIX). These companies are all part of the "medical" sector. resTORbio vs. Journey Medical XBiotech Procaps Group Pliant Therapeutics Immunic TuHURA Biosciences Galectin Therapeutics Ventyx Biosciences BioHarvest Sciences Anixa Biosciences Journey Medical (NASDAQ:DERM) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment. Does the media favor DERM or TORC? In the previous week, Journey Medical had 16 more articles in the media than resTORbio. MarketBeat recorded 16 mentions for Journey Medical and 0 mentions for resTORbio. Journey Medical's average media sentiment score of 0.60 beat resTORbio's score of 0.00 indicating that Journey Medical is being referred to more favorably in the media. Company Overall Sentiment Journey Medical Positive resTORbio Neutral Does the MarketBeat Community prefer DERM or TORC? resTORbio received 135 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 67.14% of users gave resTORbio an outperform vote. CompanyUnderperformOutperformJourney MedicalOutperform Votes6100.00% Underperform VotesNo VotesresTORbioOutperform Votes14167.14% Underperform Votes6932.86% Do institutionals and insiders believe in DERM or TORC? 7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 46.2% of resTORbio shares are owned by institutional investors. 13.2% of Journey Medical shares are owned by company insiders. Comparatively, 11.8% of resTORbio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is DERM or TORC more profitable? resTORbio has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. resTORbio's return on equity of -78.12% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-31.74% -132.10% -26.90% resTORbio N/A -78.12%-71.63% Do analysts rate DERM or TORC? Journey Medical presently has a consensus target price of $9.67, suggesting a potential upside of 58.21%. Given Journey Medical's stronger consensus rating and higher possible upside, analysts clearly believe Journey Medical is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, DERM or TORC? Journey Medical has higher revenue and earnings than resTORbio. Journey Medical is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.13M2.27-$3.85M-$0.74-8.26resTORbioN/AN/A-$82.74M-$2.41-0.34 Which has more risk and volatility, DERM or TORC? Journey Medical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. SummaryJourney Medical beats resTORbio on 12 of the 18 factors compared between the two stocks. Remove Ads Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.26M$6.90B$5.63B$7.84BDividend YieldN/A2.76%5.33%4.01%P/E Ratio-0.467.2623.5518.73Price / SalesN/A218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book0.376.386.894.23Net Income-$82.74M$142.34M$3.20B$247.47M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.83-2.3%N/A-64.7%$30.26MN/A-0.46N/ADERMJourney Medical2.5215 of 5 stars$5.31+1.1%$9.67+82.0%+66.0%$110.93M$57.77M-5.6590Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXBITXBiotech1.2376 of 5 stars$3.52+6.3%N/A-61.9%$107.30M$4.01M-3.26100Short Interest ↓Positive NewsGap UpPROCProcaps GroupN/A$0.95-40.3%N/A-67.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumePLRXPliant Therapeutics4.1928 of 5 stars$1.70+10.4%$13.31+683.1%-90.1%$104.10M$1.58M-0.5190Short Interest ↑High Trading VolumeIMUXImmunic2.6226 of 5 stars$1.14-0.9%$12.67+1,011.1%-9.1%$102.69MN/A-0.9370Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHURATuHURA BiosciencesN/A$2.42+6.1%$13.00+437.2%N/A$102.33MN/A0.00N/AGALTGalectin Therapeutics1.5267 of 5 stars$1.61-4.2%$11.00+583.2%-36.4%$101.05MN/A-2.219News CoveragePositive NewsVTYXVentyx Biosciences2.1823 of 5 stars$1.41flat$10.00+609.2%-78.0%$100.29MN/A-0.6030Positive NewsBHSTBioHarvest SciencesN/A$5.94+1.5%$13.00+118.9%N/A$97.56M$22.43M-4.76N/AHigh Trading VolumeANIXAnixa Biosciences3.1292 of 5 stars$3.03+2.4%$8.50+180.5%-4.8%$97.56M$210,000.00-7.775Analyst ForecastAnalyst RevisionNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies Journey Medical Alternatives XBiotech Alternatives Procaps Group Alternatives Pliant Therapeutics Alternatives Immunic Alternatives TuHURA Biosciences Alternatives Galectin Therapeutics Alternatives Ventyx Biosciences Alternatives BioHarvest Sciences Alternatives Anixa Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TORC Stock Free TORC Stock Alerts